echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > After 8 months, Takeda pharmaceutical completed the acquisition of shire!

    After 8 months, Takeda pharmaceutical completed the acquisition of shire!

    • Last Update: 2019-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Takeda pharmaceutical is expanding its business coverage and maintaining an attractive leading position in Japan and the United States Its employees around the world are committed to providing top-notch innovative drugs to about 80 countries or regions Takeda pharmaceutical focuses on the research of cancer, digestion, neuroscience and rare diseases, and promises to invest in research and development of blood products (PDT) and vaccines Takeda pharmaceutical's robust and highly innovative R & D engine will focus more on the innovation of breakthrough therapies and create a more global, stable and diversified product pipeline After the merger, Takeda pharmaceutical will have a total annual revenue of more than 30 billion US dollars, mainly from core business areas such as cancer, digestion, neuroscience, rare diseases and blood products (PDT) Christophe Weber, global president and CEO of Takeda pharmaceutical, said: "we are pleased that the acquisition was approved by the overwhelming majority of shareholders at the Takeda pharmaceutical general meeting held on December 5, 2018 We are also very pleased that with the efforts of Takeda pharmaceutical and (former) shire and the successful approval of the regulatory authorities, the acquisition can be completed several months ahead of schedule We would like to thank employees, partners and shareholders for their support throughout the acquisition process This is an important historical moment of Takeda pharmaceutical, marking an exciting step on the road of accelerating transformation With the expansion of our enterprise scale and business coverage, we will provide more innovative drugs for patients around the world " Mr Weber added that "the integration work starts today We are confident that under the leadership of the experienced Takeda pharmaceutical executive team, we can successfully complete the integration and achieve outstanding results In September 2018, our business model set a clear framework for the integration plan, and we formed an experienced professional integration team to lead the whole process " In order to fund the acquisition, Takeda pharmaceutical obtained long-term financing at a very competitive price, and the mixed interest rate of Takeda pharmaceutical's total debt is about 2.3% Takeda is confident that it will maintain its investment credit rating and restore its net debt and EBITDA to 2.0 times or even lower within three to five years after the acquisition.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.